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SUMMARY 
Immune response (Ir) genes, originally proposed by Baruj Benacerraf to explain 
differential antigen-specific responses in animal models, have become synonymous 
with the major histocompatibility complex (MHC). We discovered a non-MHC-linked Ir 
gene in a T cell receptor (TCR) locus that was required for CD8+ T cell responses to the 
Plasmodium berghei GAP5040-48 epitope in mice expressing the MHC class I allele H-
2Db. GAP5040-48-specific CD8+ T cell responses emerged from a very large pool of naive 
Vβ8.1+ precursors, which dictated susceptibility to cerebral malaria and conferred 
protection against recombinant Listeria monocytogenes infection. Structural analysis of 
a prototypical Vβ8.1+ TCR-H-2Db-GAP5040-48 ternary complex revealed that germline-
encoded complementarity-determining region 1β residues present exclusively in the 
Vβ8.1 segment mediated essential interactions with the GAP5040-48 peptide. 
Collectively, these findings demonstrated that Vβ8.1 functioned as an Ir gene that was 
indispensable for immune reactivity against the malaria GAP5040-48 epitope.  
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INTRODUCTION 
Genetic regulation of the immune system is a central determinant of health and 
disease. Based on the observation that random-bred guinea pigs challenged with 
simple antigens segregate into responder and non-responder groups, Benacerraf and 
colleagues proposed the notion of autosomal dominant immune response (Ir) genes 
(Benacerraf and Germain, 1978). Ir genes were first identified as major 
histocompatibility complex (MHC)-linked (McDevitt and Chinitz, 1969), and 
subsequently found to encode specific allotypes of antigen-presenting molecules, such 
as MHC class II (MHC II) (Benacerraf, 1974; Benacerraf and McDevitt, 1972). Although 
unidentified at the time, a determinative role was also suggested for the putative T cell 
receptor (TCR) (Benacerraf and Germain, 1978). MHC II-mediated antigen presentation 
is required to activate T helper cells and generate antibody responses to T-dependent 
antigens (Owens and Zeine, 1989). In addition, the host must assemble TCRs capable 
of engaging specific MHC-peptide (MHCp) complexes with sufficient avidity to trigger 
immune reactivity (Davis et al., 2003; van der Merwe and Dushek, 2011). Numerous 
studies of inbred animals have linked the absence of specific immune responses with a 
lack of appropriate MHC alleles (Marshak et al., 1977; Zinkernagel, 1978). In contrast, 
despite major advances in our understanding of antigen recognition over the last four 
decades, it remains unclear if germline-encoded segments of the TCR can function as Ir 
genes. 
CD8+ T cells recognize MHC I-restricted peptides via heterodimeric TCRs (Davis 
and Bjorkman, 1988; Townsend et al., 1985). A vast number of different TCRs can be 
generated from a limited number of germline-encoded segments through the process of 
V(D)J gene recombination with junctional diversification and subsequent random pairing 
of the somatically rearranged TCRα and TCRβ chains (Cabaniols et al., 2001; Chothia 
et al., 1988; Davis and Bjorkman, 1988; Rossjohn et al., 2015; Turner et al., 2006). As a 
consequence, each individual harbors an extensive repertoire of naive CD8+ T cells, 
which ensures broad recognition of a large number of foreign antigens presented by 
MHC I (Goldrath and Bevan, 1999). To meet the diversity criterion within space 
limitations, however, only a few naive precursors are specific for any given epitope 
(Blattman et al., 2002; Obar et al., 2008), and robust antigen-driven proliferation is 
	 	
required to establish effector and memory CD8+ T cell populations (Busch et al., 1998; 
Goldrath and Bevan, 1999). It is estimated that most naive antigen-specific repertoires 
in mice do not contain more than 10–300 CD8+ T cells (Obar et al., 2008). Larger pre-
immune repertoires comprising 1,000–1,500 naive CD8+ T cells have been reported for 
the murine cytomegalovirus (MCMV) M45985-993 and vaccinia virus (VacV) B8R20-27 
epitopes (Jenkins and Moon, 2012), but it remains unclear if these specific precursor 
pools define the upper limits of antigen reactivity in the post-thymic landscape of 
clonotypically distributed TCRs. 
 Clonal selection ensures the recruitment of biologically and structurally optimal 
immune receptors from the naive repertoire (Malherbe et al., 2004; Price et al., 2005), 
frequently leading to biased TCR usage among memory CD8+ T cell populations (Miles 
et al., 2011; Turner et al., 2006). In extreme cases, non-peptidic antigens restricted by 
non-classical MHC molecules elicit innate-like responses dominated by semi-invariant 
TCRs (Bendelac et al., 1997; Godfrey et al., 2015; Van Rhijn et al., 2015). Here, we 
found that a similar phenomenon can regulate conventional CD8+ T cell immunity. We 
demonstrated that an epitope from the Plasmodium berghei (P. berghei) ANKA 
glideosome-associated protein (GAP5040-48), a key pathogenic target in experimental 
cerebral malaria (ECM), was associated with the largest naive CD8+ T cell repertoire yet 
described in laboratory mice (Jenkins and Moon, 2012). We also revealed the molecular 
properties of these GAP5040-48-specific TCRs, demonstrating exclusive use of the Vβ8.1 
segment underpinned by direct interactions with the malarial peptide. Mice lacking the 
Vβ8.1 gene did not respond to the GAP5040-48 epitope after P. berghei infection and did 
not develop ECM. Moreover, the very large pool of naive precursors conferred 
enhanced control of primary infection with recombinant Listeria monocytogenes (L. 
monocytogenes) expressing the GAP5040-48 epitope. Collectively, these findings extend 
the notion of Ir genes to incorporate germline-encoded components of antigen-specific 
TCRs.  
 
 
 
	 	
RESULTS 
 
GAP5040-48-specific CD8+ T cells exhibit an extreme TCR bias  
 ECM in susceptible C57Bl/6 (B6) mice infected with P. berghei ANKA (Engwerda 
et al., 2005) is a valuable model of severe malarial disease (Brewster et al., 1990). It is 
established that the development of ECM is critically dependent on pathogenic CD8+ T 
cells (Amani et al., 2000; Haque et al., 2011; Yanez et al., 1996) expressing Vβ8+ TCRs 
(Boubou et al., 1999; Mariotti-Ferrandiz et al., 2016), especially those specific for the H-
2Db-restricted GAP5040-48 epitope (Howland et al., 2013). However, it is not known why 
GAP5040-48-specific CD8+ T cells are pathogenic in ECM. To address this issue, we set 
out to generate TCR retrogenic mice harboring monoclonal or oligoclonal CD8+ T cell 
populations specific for individual epitopes derived from P. berghei, namely 
thrombospondin-related adhesion protein (TRAP)130-138, sporozoite-specific protein 20 
(S20)318-326 and GAP5040-48 (Holst et al., 2006; Hafalla et al., 2013; Howland et al., 
2013). As a first step, we immunized three separate groups of B6 mice with peptide-
pulsed dendritic cells (DCs) followed 7 days later by recombinant L. monocytogenes 
expressing the same epitope (LM-GAP5040-48). This accelerated prime-boost approach 
(Badovinac et al., 2005) elicited large CD8+ T cell responses specific for TRAP130-138, 
S20318-326 and GAP5040-48 (Fig. S1A). We then used the corresponding MHC I tetramers 
and a panel of anti-mouse Vβ antibodies to profile the constituent malaria-specific 
TCRs.  
  CD8+ T cells specific for TRAP130-138 and S20318-326 expressed several different 
TCR Vβ segments with distinct preferences (Fig. 1A and S1B). For example, almost 
75% of the S20318-326-specific repertoire was focused on Vβ8.1/8.2 and Vβ8.3, while the 
TRAP130-138-specific repertoire was dominated by Vβ2 and Vβ7. In contrast, >99% of 
GAP5040-48-specific CD8+ T cells expressed Vβ8.1/8.2, which cannot be discriminated 
by antibody staining (Fig. 1A and S1B). These segments comprised <15% of the 
corresponding GAP5040-48 tetramer– repertoires in the same mice (Fig. 1B). Moreover, 
an identical TCR bias was observed after inoculation of sporozoites by mosquito bite or 
immunization with radiation-attenuated sporozoites or DC-GAP5040-48 alone (data not 
shown), and similar results were obtained with other strains of mice expressing the 
	 	
MHC I allele H-2Db, including CB6F1 and BALB.b (Fig. S1C). The GAP5040-48 epitope 
therefore mobilized an almost exclusive repertoire of TCR Vβ-defined memory CD8+ T 
cells. 
  To gain a deeper understanding of this extreme bias, we sorted GAP5040-48-
specific CD8+ T cells directly ex vivo from DC-LM-GAP5040-48-immunized B6 mice and 
performed an unbiased molecular analysis of all expressed TRA and TRB gene 
rearrangements (Quigley et al., 2011). Sequence analysis showed that >98% of 
transcripts encoded Vβ8.1 (Fig. 1C and Table S1). In contrast, a variety of TRAV gene 
segments were detected, indicating promiscuous pairing of diverse TCRα chains with a 
constrained repertoire of Vβ8.1+ TCRβ chains (Fig. 1D). Almost 40% of retrogenic T 
cells generated with a GAP5040-48-specific TCRβ chain bound the GAP5040-48 tetramer 
in naive mice, while only ~1% of retrogenic T cells generated with a TRAP130-138-specific 
TCRβ chain bound the TRAP130-138 tetramer (Fig. S2). These data suggested that the 
Vβ8.1 segment was a major recognition element for GAP5040-48-specific CD8+ T cells.   
  Analysis of the third TCRβ chain complementarity-determining region (CDR3β) 
revealed additional features of the GAP5040-48-specific repertoire (Fig. S3A–C, Table 
S1). In particular, we identified a common CDR3β length (~60% of translated 
sequences incorporated 14 amino acids) (Fig. S3A), an almost uniform bias towards 
TRBD2 gene usage within a single reading frame (Fig. S3B) and a strong preference for 
TRBJ gene segments from the Jβ2 cluster (Fig. S3C). Moreover, the Vβ-Dβ junction 
lacked N additions, and a germline-encoded CDR3β motif (104CASSDWG110) was 
present in >95% of sequences (Table S1 and Fig. 1E). These data demonstrated that a 
highly convergent pattern of gene rearrangements “licensed” the Vβ8.1-driven immune 
response to the GAP5040-48 epitope (Quigley et al., 2010). 
 
The C-terminal region of the GAP5040-48 peptide is a “hotspot” for TCR recognition 
 To understand the molecular basis of this extreme TCR bias, we first determined 
the structure of the H-2Db-GAP5040-48 complex at a resolution of 2.2 Å (Table S2). The 
bound peptide adopted a canonical extended conformation (Young et al., 1994), with 
four solvent-exposed amino acid residues (P4-L, where L is leucine; P6-A, where A is 
	 	
alanine; P7-K, where K is lysine; and P8-Y, where Y is tyrosine) representing potential 
contacts for the TCR (Fig. 2A). 
 To determine which GAP5040-48 residues were important for TCR recognition, we 
replaced individual amino acids with alanine (Ala), except for the wildtype (wt) Ala 
residue at position 6 (P6), which was replaced with serine (Ser) (Fig. 2B). We did not 
mutate the critical H-2Db anchor residues at P5 or P9 (Valkenburg et al., 2013). The wt 
and mutant peptides were then used at saturating concentrations in intracellular 
cytokine staining assays to determine the impact of each residue on the functional 
reactivity of GAP5040-48-specific CD8+ T cells (Fig. 2C and S4). Interferon-γ (IFNγ) 
production relative to the wt peptide was unaffected by the substitutions at P1, P2 and 
P3 (Fig. 2C). In contrast, the mutations at P4-L and P6-A diminished IFNγ production, 
while the mutations at P7-K and P8-Y abolished IFNγ production (Fig. 2C). The C-
terminal P7-K and P8-Y residues were therefore crucial for GAP5040-48-specific CD8+ T 
cell activation and represented “hotspots” for TCR engagement (Fig. 2D). 
 
GAP5040-48 peptide “hotspots” interact exclusively with the TCRβ chain 
 Next, we determined the structure of a prototypical Vβ8.1+ TCR, derived from the 
GAP5040-48-specific CD8+ T cell clone NB1 (Table S3), in complex with H-2Db-GAP5040-
48 (Fig. 3A, Table S2). The NB1 TCR docked centrally atop the H-2Db cleft, with an 
angle of 43° and a buried surface area (BSA) of approximately 2,200 Å2, values that fall 
within the range previously determined for TCR-MHCp complexes (Rossjohn et al., 
2015) (Fig. 3B). All six CDR loops were involved to a varying extent in the interaction 
with H-2Db-GAP5040-48 (Fig. 3C). Namely, the CDR3α and CDR3β loops contributed 
24% and 20% of the BSA, respectively, while the CDR1α and CDR2α loops each 
contributed ~17% of the BSA (Fig. 3C). Somewhat unexpectedly given the extreme 
TCR Vβ bias, the germline-encoded CDR1β and CDR2β loops each contributed only 
~10% of the BSA. Thus, the cumulative β chain contribution to the overall BSA was 
substantially smaller (39%) relative to the cumulative α chain contribution (61%) (Fig. 
3C). However, >95% of TCR-GAP5040-48 peptide interactions were mediated by the 
TCRβ chain (Fig. 3D, Table S4), while the TCRα chain primarily contacted the MHC 
molecule (74% of the BSA) (Fig. 3E, Table S4).  
	 	
 The CDR1α loop stretched between the peptide-binding α-helices of H-2Db, with 
tyrosine (Tyr) 28α playing a principal role by contacting glutamic acid (Glu)163, Glu166 
and tryptophan (Trp)167 at the N-terminal end of the cleft (Fig. 3F, Table S4). The 
CDR2α loop sat above the α2-helix, with arginine (Arg)57α lying flat above residues 
Glu154 and Ala158 (Fig. 3G). The CDR3α loop contacted a large stretch of the α1-helix 
(spanning residues 58–72), with hydrophobic and hydrogen bond contacts exclusively 
mediated by germline-encoded residues from the Jα segment (108YAQ110, where Q is 
glutamine) (Fig. 3H). The NB1 TCRα chain engaged the H-2Db molecule with a large 
footprint over the N-terminal region of the antigen-binding cleft (Fig. 3B). Mutational 
analyses of H-2Db binding performed using three distinct GAP5040-48-specific CD8+ T 
cell clones further indicated that different Vβ8.1+ TCRs used an identical MHC I docking 
strategy (Fig. S5, Table S5).  
 Interactions between the NB1 TCRα chain and the GAP5040-48 peptide were 
limited to two van der Waals interactions between the CDR3α loop and P4-L (Table S4). 
In contrast, the NB1 TCR Vβ8.1 region dominated contacts with the bound epitope (44 
of 46 contacts) (Table S4). Moreover, all three CDRβ loops contacted the C-terminus of 
the peptide (P6–8) (Fig. 3I–K), encompassing the previously identified “hotspots” for 
CD8+ T cell recognition (Fig. 2D). The CDR1β loop interacted with both P7-K and P8-Y 
via its 28N-DY31 motif (where N is asparagine and D is aspartic acid). More specifically, 
P7-K and P8-Y formed a notch in which aspartic acid (Asp)30β was inserted as a peg, 
forming a salt bridge with P7-K (Fig. 3J). In addition, asparagine (Asn)28β hydrogen 
bonded via its main chain with P7-K, while the aromatic group of Tyr31β sat above P8-Y 
(Fig. 3J). Contacts were also established between P8-Y and the CDR2β loop via Tyr57. 
Accordingly, P8-Y was closely sequestered upon TCR binding (Fig. 3J). The conserved 
CDR3β motif 108DW109 (where W is tryptophan), which was most frequently germline-
encoded within the D gene (Fig. 1E), interacted with P6-A and P7-K (Fig. 3K). The large 
Trp109β side chain lay flat on the top of P6-A, acting as a lid covering the central part of 
the epitope, while Asp108β and P7-K formed a salt bridge (Fig. 3K). 
 TCRβ chain interactions with the H-2Db molecule were modest in comparison to 
the TCRα chain (Table S4). The CDR1β loop contacted only glutamine (Gln)72 via 
Tyr31β (Fig. 3I, J). The side chains of valine (Val)58β from the CDR2β loop abutted 
	 	
Val76 from H-2Db, establishing an interaction network extended by Tyr57b-mediated 
contacts with Gln72, Arg75 and Val76. The conserved CDR3β 108DW109 motif from the 
TRBD2 gene segment formed interactions with the hinge region of the α2-helix, 
whereby Trp109β nestled between histidine (His)155 and Ser150. Thus, germline-
encoded TCRb chain residues played a minor role in contacting the H-2Db molecule. 
 The observation that the prototypical NB1 TCR interacted with GAP5040-48 
extensively via its β chain suggested that the peptide itself drove the extreme bias 
towards Vβ8.1. This notion contrasts with prevailing dogma, which asserts that germline 
bias arises as a consequence of allotype-specific MHC reactivity (Garcia et al., 2009).  
 
CDR1 residues unique to Vβ8.1 are critical for GAP5040-48 peptide recognition 
 These structural insights allowed us to identify candidate factors underlying the 
exclusive recruitment of Vβ8.1+ TCR clonotypes into the immune repertoire. To 
determine the precise amino acid sequences involved in this process, we initially 
focused on the germline-encoded CDR1β and CDR2β loops. Sequence alignments 
revealed that the CDR1β loops encoded by six TRBV genes shared a common Asp30β, 
while the Asp30β-Tyr31β motif was unique to Vβ8.1. In the other five TRBV genes, 
Tyr31β was replaced by a smaller threonine (Thr)/Ser residue (Table S6A). Three TRBV 
genes shared a common Val58β residue in the encoded CDR2β loop, but only Vβ8.1 
incorporated the additional Tyr57β required to sequester P8-Y (Table S6B).  
 Although the conserved CDR3β region interacted with both the peptide and H-
2Db, we wanted to determine if the germline-encoded Vβ8.1 residues were essential for 
TCR-mediated recognition of H-2Db-GAP5040-48. We therefore conducted affinity 
measurement studies using targeted mutants of the NB1 TCR. Ala mutagenesis was 
performed on residues Asp30β and Tyr31β in the CDR1β loop and residues Tyr57β and 
Val58β in the CDR2β loop (Fig. 4A and B). In addition, Tyr31β was mutated to Thr to 
mimic the CDR1β loop encoded by the five other TRBV genes that share Asp30β (Fig. 
4A and B). Affinity values for each TCR mutant, measured by surface plasmon 
resonance (SPR), were compared with the affinity of the wt TCR. The results showed 
that mutations in the CDR2β loop exerted a moderate effect, decreasing binding affinity 
by 3-fold compared with the NB1 TCR (Fig. 4A and B). In contrast, mutation of Tyr31β 
	 	
to either Ala or Thr in the CDR1β loop substantially reduced binding to H-2Db-
GAP5040-48, resulting in Kdeq values >200 μM (Fig. 4A and B). As shown in Fig. 3I and 
Table S4, Tyr31β contacted both H-2Db and P8-Y. Additionally, mutation of Asp30β to 
Ala abolished binding to H-2Db-GAP5040-48 (Fig. 4A and B). The Asp30β residue 
contacted the peptide alone via a salt bridge with P7-K, one of the two defined “hotspot” 
residues for TCR recognition (Fig. 3J and Table S4). 
  The unique germline-encoded CDR1β 30DY31 motif within the Vβ8.1 segment 
therefore underpinned both the extreme TCR bias and the residue-specific patterns of 
epitope recognition that characterized the CD8+ T cell response to H-2Db-GAP5040-48.  
 
The naive GAP5040-48-specific CD8+ T cell repertoire is extraordinarily large 
 Extreme TCR focusing described in the literature appears to result primarily from 
the selection of high-affinity clonotypes during repeated or persistent infection (Busch 
and Pamer, 1999; Malherbe et al., 2004; Price et al., 2005; Savage et al., 1999), but 
recombinatorial bias and structural constraints dictate the available pre-immune 
repertoire (Miles et al., 2011; Neller et al., 2015; Turner et al., 2006). We therefore 
adapted a tetramer-based enrichment protocol (Moon et al., 2007) to enumerate the 
naive repertoires specific for the P. berghei epitopes TRAP130-138, S20318-326 and 
GAP5040-48. Parallel experiments were performed with tetramers representing epitopes 
derived from ovalbumin (H-2Kb-OVA257-264) and lymphocytic choriomeningitis virus 
glycoprotein (H-2Db-LCMV GP33-41) to allow comparison with previously reported 
evaluations of the naive antigen-specific T cell repertoire (Jenkins and Moon, 2012).  
 Precursor numbers specific for OVA257-264 and GP33-41 were consistent with prior 
reports (183 ± 33 and 358 ± 40 cells, respectively, Fig. 5A) (Jenkins and Moon, 2012). 
The naive S20318-326-specific repertoire was relatively small (~79 ± 19 cells), while fewer 
than 10 cells were counted in the TRAP130-138-specific repertoire (Fig. 5A). In contrast, 
as described recently (Gordon et al., 2015), the GAP5040-48-specific naive repertoire 
was extraordinarily large (2,935 ± 305 cells, Fig. 5A). The upper limit for a naive 
antigen-specific CD8+ T cell repertoire in mice was previously established at 1,200–
1,500 cells for the MCMV M45985-993 and VacV B8R20-27 epitopes (Jenkins and Moon, 
2012). The GAP5040-48-specific repertoire therefore constituted the largest naive 
	 	
antigen-specific CD8+ T cell pool yet described (Fig. 5B). Moreover, >99% of naive 
GAP5040-48-specific CD8+ T cells expressed Vβ8.1 (Fig. 5A). These findings indicated 
that the extreme TCR Vβ bias observed in the memory CD8+ T cell pool did not evolve 
as a consequence of repertoire focusing in response to antigenic challenge, but instead 
reflected intrinsic recognition of the GAP5040-48 epitope characterized by absolute 
dependence on the interaction with Vβ8.1. 
 Phenotypically, the GAP5040-48-specific precursors resembled classical naive 
CD8+ T cells, comprised of a large CD44lo population (>90%) and a small CD44hi “virtual 
memory” population (<10%) akin to OT-I and P14 TCR-Tg cells from naive mice (Fig. 
5C) (Akue et al., 2012). Expression of the CD5 surface protein, which acts as a 
surrogate marker for the strength of TCR activation induced by self-derived MHCp 
complexes during thymic selection and frequently correlates with T cell avidity for 
antigen (Fulton et al., 2015; Mandl et al., 2013), was uniformly higher on naive GAP5040-
48-specific CD8+ T cells compared with the majority of non-GAP5040-48-specific naive 
CD8+ T cells in the same host and mirrored levels expressed by OT-I cells, which 
express high-affinity TCRs (Fig. 5D) (Kedl et al., 2000). These data suggested that the 
extremely large pool of Vβ8.1+ precursors specific for the GAP5040-48 epitope arose as a 
consequence of strong thymic selection. 
 
Absence of Vβ8.1 compromises the GAP5040-48-specific CD8+ T cell response 
 The results of our structural and mutagenesis studies indicated that immune 
responses to GAP5040-48 required the presence of Vβ8.1. To test this hypothesis, we 
studied the generation of GAP5040-48-specific CD8+ T cell responses in C57/L (H-2b) 
mice, which lack Vβ8 (Behlke et al., 1986). For this purpose, C57/L mice and control B6 
mice were exposed to infection with 103 P. berghei ANKA sporozoites, a challenge that 
induces ECM in susceptible mouse strains.  
 In contrast to B6 mice, which generated GAP5040-48-specific responses 
comprising 4–5% of the total CD8+ T cell pool in peripheral blood and >10% of the total 
CD8+ T cell pool in the brain by day 7 post-infection, the GAP5040-48-specific response 
in C57/L mice was undetectable in both compartments (Fig. 6A and B). This finding 
strongly suggested that the GAP5040-48-specific CD8+ T cell response was critically 
	 	
dependent on Vβ8.1. In addition, B6 x C57/L F1 mice mounted substantial Vb8.1+ 
GAP5040-48-specific CD8+ T cell responses after infection with LM-GAP5040-48 or P. 
berghei ANKA (data not shown), excluding negative selection of GAP5040-48-specific 
naive precursors in C57/L mice. However, C57/L mice lack other Vβ genes (Vβ5, Vβ8, 
Vβ9, Vβ11 and Vβ12) (Behlke et al., 1986), which could potentially compromise the 
ability to mount alternative responses to GAP5040-48. Countering this argument, the 
magnitude of the total P. berghei-specific CD8+ T cell response, as detected by the 
frequency of CD8+ T cells expressing surrogate activation markers (CD11ahi CD8lo) (Rai 
et al., 2009) at day 7 post-infection, was essentially identical in B6 and C57/L mice (Fig. 
6C). Moreover, C57/L mice did not develop ECM, instead they survived beyond day 9 
post-infection and succumbed to high-level parasitemia after ~3 weeks (Fig. 6D).  Thus, 
the Vβ8.1 gene was necessary for the generation of detectable GAP5040-48-specific 
CD8+ T cell responses and the development of ECM.  
 
GAP5040-48-specific CD8+ T cells are pathogenic in ECM  
 A recent publication suggested that GAP5040-48-specific CD8+ T cells play a key 
role in the pathogenesis of ECM in susceptible B6 mice (Howland et al., 2013). 
Mechanistically, accumulation of GAP5040-48-specific CD8+ T cells in the brain could 
lead to eventual rupture of the blood-brain-barrier, which triggers well recognized 
neurological symptoms leading to rapid death (7–9 days post-infection) (Howland et al., 
2013). In contrast to susceptible B6 mice, which all succumbed to ECM by day 7 post-
infection with P. berghei ANKA-parasitized red blood cells (pRBCs), only 20% of CB6F1 
mice succumbed to ECM (Fig. 6E). We therefore considered the possibility that a strain-
specific difference in the size of the naive GAP5040-48-specific CD8+ T cell repertoire 
might underlie these differential outcomes. Tetramer pull-down of naive GAP5040-48-
specific CD8+ T cells revealed that CB6F1 mice harbored ~3-fold fewer precursors than 
B6 mice (Fig. 6F). Moreover, this smaller naive pool resulted in a smaller GAP5040-48-
specific CD8+ T cell response in CB6F1 mice compared with B6 mice at day 6 post-
infection with P. berghei ANKA pRBCs (Fig. 6G). These results suggested that a 
GAP5040-48-specific CD8+ T cell response threshold might be required for the induction 
of ECM. To confirm a threshold-dependent pathogenic role for GAP5040-48-specific 
	 	
CD8+ T cells in ECM, we generated a large GAP5040-48-specific CD8+ T cell response in 
CB6F1 or B6 mice prior to infection with P. berghei ANKA. We observed no meaningful 
difference in the onset of ECM symptoms or the mortality rate between previously 
immunized and non-immunized B6 mice, demonstrating that sufficient numbers of 
GAP5040-48-specific effector CD8+ T cells can be generated from the large pool of naive 
precursors in this susceptible strain (Fig. 6H). In contrast, prior immunization against 
GAP5040-48 was required to render all CB6F1 mice susceptible to ECM after P. berghei 
ANKA infection (Fig. 6I). Collectively, these findings demonstrated that a numerical 
threshold delimited the pathogenicity of GAP5040-48-specific CD8+ T cells in the etiology 
of ECM. 
 
GAP5040-48-specific CD8+ T cells protect against LM-GAP5040-48 
 Although pathogenic in the context of ECM, we hypothesized that the rapid 
generation of a substantial GAP5040-48-specific response from the large number of naive 
precursors may protect against infection controlled primarily by CD8+ T cells. To 
address this possibility, we determined if B6 mice could better control primary infection 
with virulent LM-GAP5040-48 compared with virulent wt LM. 
 To ensure comparability, we first established that the two different strains of LM 
exhibited similar virulence in the absence of a GAP5040-48-specific CD8+ T cell 
response. For this purpose, we infected BALB/c mice (H-2d), which were non-
responsive to the H-2Db-restricted GAP5040-48 epitope (Fig. 7A). Bacterial burden 
assessed in the spleens of infected mice 5 days after infection with 5 x 103 colony-
forming units (CFU) of each strain was similar between the two groups, suggesting 
equivalent virulence in vivo (Fig. 7B). In contrast, we measured ~10-fold fewer bacteria 
in the spleens of LM-GAP5040-48-infected B6 mice compared with wt LM-infected B6 
mice (Fig. 7C–D). This superior control of bacterial infection in LM-GAP5040-48-infected 
B6 mice was accompanied by a large GAP5040-48 specific response, comprising >8% of 
the total CD8+ T cell pool in the spleen (Fig. 7E). The expansion of GAP5040-48-specific 
effector cells from a large pool of naive precursors therefore conferred protection in the 
context of an infection controlled by CD8+ T cells. 
	 	
DISCUSSION 
 Conceptual frameworks developed in the 1970s, prior to a detailed 
understanding of the molecular interactions that govern T cell antigen recognition, 
established the notion of genetically controlled immune responsiveness. Overwhelming 
experimental data have since accumulated to validate one original proposition that 
MHC-linked Ir genes dictate the presentation of specific antigens in immunogenic form 
(Benacerraf and Germain, 1978). There is also some evidence to support the idea that 
germline-encoded components of the TCR interact preferentially with defined MHC 
allotypes (Garcia et al., 2009; Scott-Browne et al., 2009), building on the earlier 
theoretical work of Niels Jerne (Jerne, 1971). However, it has not been shown 
previously that heritable elements of an antigen receptor can license immune reactivity, 
a scenario postulated almost four decades ago as an alternative model to explain the Ir 
gene phenomenon (Benacerraf and Germain, 1978). In this study, we demonstrated 
that CD8+ T cell responses specific for the murine malaria epitope GAP5040-48 were 
entirely dependent on amino acid residues unique to the TCR Vβ8.1 segment, thereby 
providing insights into the genetic mechanisms that control adaptive immunity.  
 As a consequence of structural constraints focused primarily on the CDR1β loop, 
both naive and antigen-expanded H-2Db-restricted GAP5040-48-specific CD8+ T cells 
almost invariably express Vβ8.1+ TCRs. Similarly extreme biases are typically 
associated with innate-like responses to non-peptidic antigens presented by non-
classical MHC molecules, although immune reactivity among these unconventional T 
cell subsets is generally endowed by a conserved TCRa chain (Van Rhijn et al., 2015). 
Narrow TCR repertoires specific for peptide epitopes have previously been linked with 
low numbers of naive precursors (Moon et al., 2007) and clonal selection during the 
genesis of memory populations, especially in the presence of constant or repetitive 
antigen stimulation (Busch and Pamer, 1999; Price et al., 2005; Savage et al., 1999). 
Paradoxically, the pre-immune GAP5040-48-specific repertoire was the largest yet 
described in mice, numbering ~3,000 cells in a naive B6 host. Moreover, this substantial 
precursor pool did not seem to arise as a consequence of expansion into the virtual 
memory subset (Haluszczak et al., 2009), as >90% of naive GAP5040-48-specific CD8+ T 
cells expressed low levels of CD44 (Akue et al., 2012). Although the self-derived 
	 	
peptides associated with positive selection of these antigen-specific precursors remain 
unknown, the uniformly high expression of CD5 by naive GAP5040-48-specific CD8+ T 
cells suggested the existence of strong TCR-mediated interactions in the thymus (Mandl 
et al., 2013). It is also notable that Vβ8 gene segments are highly represented in 
laboratory mouse strains (Wilson et al., 2001). High numbers of naive GAP5040-48-
specific CD8+ T cells therefore most likely emerged as a consequence of both 
permissive thymic selection and the frequent generation of Vβ8.1+ transcripts during the 
process of somatic recombination. In addition, the presence of a highly conserved Vβ-
Dβ junction lacking N additions suggested that convergent gene rearrangements, which 
occur more commonly on a probabilistic basis (Quigley et al., 2010), effectively licensed 
the extreme penetrance of the Vβ8.1 gene-encoded phenotype.  
 So what are the immunological consequences of such a large pool of antigen-
specific precursors in the naive CD8+ T cell compartment? Earlier work indicated that 
CD8+ T cells expressing Vb8.1/Vb8.2+ TCRs are highly prevalent during malaria 
infection and contribute to the pathogenesis of ECM (Mariotti-Ferrandiz et al., 2016). In 
addition, it had been shown previously that high-dose tolerization with the GAP5040-48 
peptide abrogates disease susceptibility in B6 mice (Howland et al., 2013). These 
observations can be explained by our finding that an extremely large pool of Vb8.1+ 
antigen-specific naive precursors (~3,000 cells) underpinned the immunodominant 
CD8+ T cell response to GAP5040-48 and the susceptibility of B6 mice to ECM. In 
contrast, CB6F1 mice harbored a diminished pool of antigen-specific naïve precursors 
(~1,000 cells), leading to smaller GAP5040-48-specific CD8+ T cell responses and relative 
resistance to ECM. This causal association was confirmed by the observation that 
increasing the number of GAP5040-48-specific CD8+ T cells in CB6F1 mice prior to 
infection rendered them susceptible to ECM. It remains unclear if similar germline 
biases can dictate immune responses to malarial antigens in humans, but our data 
nonetheless provide proof-of-concept that genetic associations with disease outcome 
can be extended to loci encoding components of the TCR. Moreover, the peak 
incidence of severe anemia during malaria infection occurs in children under 2 years of 
age, while cerebral malaria occurs most commonly in children aged 3–5 years who 
have prior exposure to infection (Struik and Riley, 2004). These epidemiological 
	 	
patterns are consistent with the possibility that larger pre-infection repertoires of malarial 
antigen-specific T cells predispose to the development of cerebral malaria.   
 GAP5040-48-specific memory CD8+ T cells are not protective during the liver-stage 
of murine malaria (Doll et al., 2016; Horne-Debets et al., 2016; van der Heyde et al., 
1993; Vinetz et al., 1990), and the capacity of CD8+ T cells to protect during blood-stage 
malaria remains controversial (Horne-Debets et al., 2016; Imai et al., 2010; van der 
Heyde et al., 1993; Vinetz et al., 1990). Thus, the pathogenic effects of GAP5040-48-
specific CD8+ T cells in ECM most likely resulted from a large population of precursors, 
which expanded rapidly after infection to generate substantial numbers of effector cells, 
leading to sustained immune activation without elimination of the pathogen. In contrast, 
rapid expansion from the same population of precursors enhanced immune control of 
primary infection with L. monocytogenes expressing the GAP5040-48 epitope. An 
unusually large naive CD8+ T cell pool can therefore be pathogenic or protective, 
depending on the nature of the infectious challenge.  
 In conclusion, our data provide direct evidence that a germline-encoded TCR 
segment can determine immune responsiveness to an exogenous peptide antigen, 
thereby extending the concept of Ir genes beyond the MHC. The unique features 
associated with this phenomenon may allow novel interventions to improve vaccine 
efficacy and limit immune pathology in humans, pending further studies to identify 
similar genetic associations between disease outcome and heritable components of the 
TCR. 
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FIGURE LEGENDS 
 
Figure 1: GAP5040-48-specific CD8+ T cells express biased TCRs 
(A, B) Mice were primed with peptide-coated DCs and boosted on day 7 with 
recombinant L. monocytogenes expressing the same epitope. (A) The TCR Vβ 
repertoire was assessed using splenocytes isolated from immunized mice by staining 
with the indicated tetramers and Vβ-specific antibodies. Results are shown for two mice 
for each antigen specificity. Data represent four independent experiments (n = 5 
mice/group). Cumulative data are shown in Supplementary Figure 1B. (B) Extreme 
focusing of the GAP5040-48-specific repertoire does not reflect the overall frequency of 
Vβ8.1/8.2+ clonotypes in the CD8+ T cell compartment. Data represent three 
independent experiments (n = 4–5 mice/group). (C, D) Confirmation of TCR bias at the 
transcriptional level. Sequences were derived from GAP5040-48-specific CD8+ T cells 
isolated from the spleens of mice previously immunized with DC-LM-GAP5040-48 (total = 
316 molecular clones). (C) Population-level analysis revealed an extreme bias towards 
Vβ8.1. (D) TCR Va sequence distributions from three different mice are depicted. No 
obvious bias was apparent in the Va repertoire. (E) Origin of CDR3β amino acids 
expressed relative to the total number of molecular Vβ8.1+ clones (n = 5 mice). Vβ: red; 
Dβ: green; Jβ: purple; N segments: white. (See also Figures S1–S3 and Table S1). 
  
Figure 2: TCR interactions focus on the C-terminal region of the GAP5040-48 
peptide 
(A) The structure of the GAP5040-48 peptide in complex with H-2Db. The GAP5040-48 
peptide is represented as black sticks in the antigen-binding cleft of H-2Db (white 
cartoon). The P2-Q and P9-L anchor residues are buried within the antigen-binding 
cleft, and P5-N acts as a secondary anchor residue forming hydrogen bonds (black 
dashes) with Gln97 (white stick) at the base of the antigen-binding cleft of H-2Db (white 
cartoon). (B) A panel of peptide mutants was generated by replacing amino acids with 
Ala or Ser at selected positions (red). Anchor residues are underlined. (C) Splenocytes 
isolated from GAP5040-48-immunized mice were restimulated for 5 h in vitro using wt or 
mutant peptides. The production of IFNγ induced by stimulation with the different mutant 
	 	
peptides is expressed relative to the production of IFNγ induced by stimulation with the 
wt peptide. Data represent two independent experiments performed in triplicate. Bars 
represent mean ± SD. Significance was assessed using a one-way ANOVA (****p < 
0.0001). (D) The effect of peptide substitutions on recognition of the H-2Db-GAP5040-48 
complex by specific CD8+ T cell clones. The surface of H-2Db is shown in white. Peptide 
residues that were not mutated or did not affect IFNγ production are shown in gray. 
Green represents up to a 25% decrease in T cell activation; orange represents up to a 
70% decrease in T cell activation; red represents a total abrogation of T cell activation. 
(See also Figure S4 and Table S2). 
 
Figure 3: GAP5040-48-specific TCR bias is peptide-driven 
(A) The crystal structure of the NB1 TCR (α chain: pink cartoon; β chain: purple cartoon) 
bound to the GAP5040-48 peptide (black sticks) presented by H-2Db (heavy chain: white 
cartoon; β2m, wheat cartoon). (B) The CDR loop contribution to the BSA is represented 
as teal (CDR1α), green (CDR2α), purple (CDR3α), red (CDR1β), orange (CDR2β) or 
yellow (CDR3β). Black spheres represent the center of mass for the Vα and Vβ. (C–E) 
The contribution (%) of the CDR loops to the interaction with H-2Db-GAP5040-48 (C), 
GAP5040-48 (D) and H-2Db (E). (F–K) Contact residues between H-2Db-GAP5040-48 and 
CDR1α (F), CDR2α (G), CDR3α (H), CDR1β (I, J), CDR2β (J) and CDR3β (K). The 
CDR color scheme is maintained though panels F–K. Residues that make contacts with 
the GAP5040-48 peptide or H-2Db (white) are depicted as black and white sticks, 
respectively. The H-2Db molecule is represented as white cartoon, and hydrogen bonds 
are shown as black dashes. (See also Figure S5 and Tables S2–S5). 
 
Figure 4: Binding affinities of NB1 TCR mutants for H-2Db-GAP5040-48  
(A) Surface plasmon resonance (SPR) analysis of NB1 wt (black) and the indicated 
mutant (colored) TCRs across a range of H-2Db-GAP5040-48 concentrations up to a 
maximum of 200 μM. Representative SPR binding curves are shown for the NB1 wt 
TCR (black) and NB1 mutant TCRs with the following β chain substitutions: Y31A 
(green), D30A (red), Y57A (pink), V58A (orange) and Y31A (blue). Each NB1 mutant 
TCR was tested in parallel with the NB1 wt TCR. (B) Summary table representing 
	 	
equilibrium binding affinities of NB1 TCR mutants for H-2Db-GAP5040-48. NB: no binding; 
RU: response units. Data represent two independent experiments performed in 
duplicate (mean ± SEM). (See also Tables S6A and S6B). 
 
Figure 5: The naive GAP5040-48-specific CD8+ T cell repertoire is extremely large  
(A) CD8+ T cells specific for OVA257-264, GP33-41, GAP5040-48, S20318-326 and TRAP130-138 
were enriched from the spleens and macroscopic lymph nodes of naive C57Bl/6 mice 
and used to calculate the final numbers of tetramer+ cells indicated in each plot. Target 
cells were identified as CD8+ CD90.2+ CD11b– CD11c– B220– tetramer(APC)+ 
tetramer(PE)+. Depicted numbers of naive precursors were calculated as mean ± SD 
from 11 mice for the GAP5040-48-specific repertoire. Right panel: Vβ8.1/8.2 expression 
on naive GAP5040-48-specific CD8+ T cells. (B) Sizes of the naive repertoires specific for 
various CD8+ T cell epitopes. The number of naive GAP5040-48-specific precursors is 
represented as a range from 2,700–3,250 cells (total n = 11 mice). (C, D) Phenotypic 
characterization of naive GAP5040-48-specific CD8+ T cells. (C) Expression of CD44 on 
naive GAP5040-48-specific CD8+ T cells was compared with CD8+ T cells obtained from 
naive Tg OT-I and P14 mice. (D) Expression of CD5 on naive GAP5040-48-specific CD8+ 
T cells was compared with total naive, non-GAP5040-48-specific CD8+ T cells (left panel) 
and with naive Tg OT-I cells (right panel). Data represent two independent experiments 
(n = 4 mice/group). Bars depict mean ± SD.   
 
Figure 6: Vb8.1 is required for the generation of GAP5040-48-specific CD8+ T cells 
and the development of ECM 
(A, B) C57Bl/6 and C57/L mice were infected with 1,000 P. berghei ANKA sporozoites. 
H-2Db-GAP5040-48 tetramer+ cells were quantified in the blood (A) and brains (B) at day 
7 post-infection (representative plots: left; summary graph: right). (C) Magnitude of the 
activated CD8+ T cell response at day 7 post-infection, expressed as % CD11ahi CD8lo 
of total CD8+ T cells (representative plots: left; summary graph: right). Naive control 
values were subtracted from individual values. Data represent two independent 
experiments (n = 3 mice/group). Bars depict mean ± SD. Significance was assessed 
using an unpaired, two-tailed t test (**p < 0.01, ***p < 0.001). (D) Survival curves for 
	 	
C57Bl/6 mice and C57/L mice after infection with P. berghei ANKA. Data represent 
three independent experiments (n = 5 mice/group). Significance was assessed using 
the Mantel-Cox log rank test (***p = 0.001). (E) C57Bl/6 and CB6F1 mice were infected 
with 106 P. berghei-parasitized red blood cells (pRBCs). Mice were monitored for the 
development of ECM symptoms and scored for survival over a period of two weeks. 
Data represent three independent experiments (n = 5 mice/group). Significance was 
assessed using the Mantel-Cox log rank test (**p = 0.0025). (F) GAP5040-48-specific 
CD8+ T cells were tetramer-enriched from naive C57Bl/6 and CB6F1 mice and 
quantified to estimate repertoire size. Cumulative results are shown from two 
independent experiments (total n = 4 mice/group). Bars depict mean ± SEM. 
Significance was assessed using an unpaired, two-tailed t test (****p <0.0001). (G) 
C57Bl/6 and CB6F1 mice were infected with 106 pRBCs. The GAP5040-48-specific CD8+ 
T cell response was followed in the blood of infected mice using H-2Db-GAP5040-48 
tetramers. All C57Bl/6 mice succumbed to ECM by days 6 and 7, while all CB6F1 mice 
survived. Data represent two independent experiments (n = 5 mice/group). Bars depict 
mean ± SD. Significance was assessed using an unpaired, two-tailed t test (****p < 
0.0001). (H, I) C57Bl/6 and CB6F1 mice were injected IV with 5 x105 GAP5040-48 
peptide-coated DCs and then infected 7 days later with recombinant attenuated LM-
GAP5040-48. At a memory time point after LM infection, DC-LM-GAP5040-48-immunized 
or non-immunized mice were infected with 106 pRBCs. Survival curves are shown for 
C57Bl/6 mice (H) and CB6F1 mice (I). Data represent two independent experiments (n 
= 5 mice/group). Significance was assessed using the Mantel-Cox log rank test (p = 
0.0993 in panel D; **p = 0.0018 in panel E). 
 
Figure 7: Large numbers of GAP5040-48-specific CD8+ T cells control primary L. 
monocytogenes infection 
(A) BALB/c mice were infected IV with 5x103 CFU of wt LM or recombinant LM-
GAP5040-48. Bacterial burden was measured in the spleen on day 5. Data represent two 
independent experiments (n = 4 mice/group). Bars depict mean ± SD. (B) C57Bl/6 mice 
were infected IV with 104 CFU of wt LM or recombinant LM-GAP5040-48. Bacterial 
burden was measured in the spleen on day 5. Cumulative results are shown from three 
	 	
independent experiments (total n = 14–15 mice/group). Bars depict mean ± SEM. 
Significance was assessed using an unpaired, two-tailed t test (****p<0.0001). (C) 
Representative flow cytometry plots showing H-2Db-GAP5040-48 tetramer staining of 
splenocytes isolated from infected C57Bl/6 mice at day 5 post-infection. 
 
	 	
METHODS 
 
Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, John T. Harty (john-harty@uiowa.edu).  
 
Experimental Model and Subject Details 
C57Bl/6 (H-2b), BALB/c (H-2d) and CB6F1 (H-2bxd) mice were purchased from the 
National Cancer Institute (Frederick, MD). BALB.b (H-2b) and C57/L (H-2b) mice were 
purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were housed with 
appropriate biosafety containment at the University of Iowa Animal Care Unit. The 
animals were treated and handled in accordance with guidelines established by the 
Institutional Animal Care and Use Committee. All experiments were performed using 
female mice, aged 6–8 weeks. P. berghei ANKA clone 234-parasitized Anopheles 
stephensi mosquitos were produced in house or obtained from New York University. For 
ECM infection, mice were injected intravenously (IV) with 103 viable sporozoites or 
intraperitoneally (IP) with 106 pRBCs. pRBCs were obtained from mice infected with a 
frozen stock 4–5 days previously. Numbers of transferred pRBCs were estimated by 
counting infected cells in Giemsa-stained blood smears. For virulent LM infection (wt or 
LM-GAP5040-48), BALB/c mice were infected IV with 5x103 CFU, and C57Bl/6 mice were 
infected IV with 104 CFU. Bacterial burden in the spleen was measured according to a 
previously published protocol (Badovinac and Harty, 2000). 
 
Method Details 
DC-LM immunizations 
For the purpose of TCR clonotyping, mice were immunized using a DC-LM prime-boost 
regimen (Badovinac et al., 2005). FMS-like tyrosine kinase-3 ligand (Flt-3L)-induced 
splenic DCs were LPS-matured, isolated after collagenase/DNAse digestion (Pham et 
al., 2009), and incubated with the following peptides for 2 h at a final concentration of 2 
μM: TRAP130-138 (SALLNUDNL), S20318-326 (VNYSFLYLF) or GAP5040-48 (SQLLNAKYL). 
CD11c+ cells were then enriched using anti-CD11c MicroBeads (Miltenyi Biotec). A total 
	 	
of 5x105 purified DCs in saline were used to prime each mouse IV. After 7 days, mice 
were boosted IV with 107 CFU of recombinant attenuated LM-TRAP130-138, LM-S20318-326 
or LM-GAP5040-48. All recombinant attenuated LM strains were both actA- and inlB-
deficient. The number of injected bacteria was verified by plating on tryptic soy agar 
supplemented with 50 μg/ml streptomycin. 
 
TCR clonotyping 
C57Bl/6 mice were immunized against GAP5040-48 using the DC-LM prime-boost 
regimen. After 5 weeks, splenocytes were isolated and stained with LIVE/DEAD Fixable 
Aqua and anti-CD16/CD32 (FCR4G8; Thermo Fisher Scientific). Antigen-specific cells 
were labeled using a BV421-conjugated version of the GAP5040-48 tetramer. Lineage 
markers were identified using anti-CD3-Cy5PE (17A2; BioLegend), anti-CD4-Alexa 
Fluor 700 (RM4-5; BD Biosciences) and anti-CD8-BV711 (53-6.7; BioLegend). Viable 
CD3+ CD4– CD8+ GAP5040-48 tetramer+ cells were then sorted at >98% purity using a 
custom-built 20-parameter FACSAria II (BD Biosciences). TCR clonotyping was 
performed from 5,000 sorted cells per mouse using a template-switch anchored RT-
PCR (Quigley et al., 2011). Amplicons were subcloned, sampled, sequenced and 
analyzed as described previously (Price et al., 2005). In all cases, TCR nomenclature 
was translated from the IMGT database via web-based alignment of molecular 
transcripts (http://www.imgt.org). 
 
Tetramer-based CD8+ T cell enrichment  
The size of the naive antigen-specific CD8+ T cell repertoire was quantified using a 
modified version of a previously published protocol (Moon et al., 2007). Spleen, 
popliteal, inguinal, brachial, axillary and cervical lymph nodes were isolated from naive 
mice and processed to a single cell suspension. Prepared cells were then labeled with 
an equimolar mixture of PE- and APC-conjugated tetramers representing each defined 
epitope. After incubation for 1 h at 4°C, cells were surface stained for CD8, CD90.2 and 
exclusion markers (B220, CD11b and CD11c). Labeled cells were subsequently 
captured and enumerated using anti-PE and anti-APC magnetic beads with an 
AutoMACS separator (Miltenyi Biotec). 
	 	
 
Peptide mutants 
Mutant GAP5040-48 peptides were generated by replacing individual amino acids with 
Ala or Ser (for P6-Ala), barring the anchor residues at P5 and P9 (BioSynthesis Inc.). 
Splenocytes were isolated from DC-LM-GAP5040-48-immunized mice during the memory 
phase (>40 days post-immunization) and restimulated for 5 h in the presence of 
brefeldin A with either wt or mutant peptides at a final concentration of 500 nM. All 
restimulations were performed in triplicate. IFNγ-producing CD8+ T cells were identified 
using a standard intracellular cytokine staining protocol (Doll et al., 2016). Data are 
expressed relative to the percentage of CD8+ T cells producing IFNγ in response to the 
wt peptide. 
 
Generation of TCRβ retrogenic mice 
TCRβ retrogenic mice were generated on a C57Bl/6 background using retrovirus-
mediated stem cell gene transfer (Bettini et al., 2013; Holst et al., 2006). The relevant 
antigen-specific TCRβ sequences were obtained from CD8+ T cell clones derived from 
mice immunized with GAP5040-48 (Vβ8.1+) or TRAP130-138 (Vβ9+).  
 
Isolation of mononuclear cells from the brains of P. berghei ANKA-infected mice  
Mononuclear cells were isolated from brain tissue using a previously published protocol 
with minor modifications (Zhao et al., 2009). Brains harvested after intravascular 
exclusion were processed and digested with collagenase D (1 mg/ml; Roche) and 
DNase (0.1 mg/ml; Sigma-Aldrich) for 30 min at 37°C. Dissociated brain tissue was then 
passed through a 70 μm nylon mesh cell strainer, spun down, resuspended and 
centrifuged for 20 min over 37% Percoll. Mononuclear cells were collected from the 
pellet, and RBCs were lysed using 1X VitaLyse (CMDG). 
 
Protein expression, purification and crystallization 
The α and β chains of the TCR clones NB1, KL1 and KL4 were expressed separately as 
inclusion bodies and refolded with engineered disulfide linkages in the constant 
domains as described previously (Day et al., 2011). Ala substitutions in the H-2Db and 
	 	
NB1 TCR sequences were introduced using site-directed mutagenesis. Soluble wt and 
mutant H-2Db heterodimers containing the GAP5040-48 peptide were prepared as 
described previously (Day et al., 2011). Crystals of H-2Db-GAP5040-48 (5 mg/ml) or the 
NB1 TCR in complex with H-2Db-GAP5040-48 (6 mg/ml) in 10 mM Tris-HCl (pH 8) and 
150 mM NaCl were grown by the hanging-drop, vapor-diffusion method at 20°C with a 
protein/reservoir drop ratio of 1:1. Crystals of free H-2Db-GAP5040-48 were obtained in 
0.1 M Tris-HCl (pH 8.5), 0.2 M lithium sulfate and 25–30% PEG8000. Crystals of the 
NB1 TCR in complex with H-2Db-GAP5040-48 were obtained in 18% PEG3350, 2% 
ethylene glycol, 0.2 M CaCl2 and 0.1 M HEPES (pH 7.2). 
 
Data collection and structure determination 
Crystals were soaked in a cryoprotectant solution containing mother liquor with the 
PEG8000 concentration increased to 30% (v/v) and then flash frozen in liquid nitrogen. 
Data were collected on the MX2 beamline at the Australian Synchrotron using the 
ADSC-Quantum 315r CCD detectors (at 100K). Data were processed with XDS 
software (Kabsch, 2010) and scaled using SCALA software (Evans, 2006) from the 
CCP4 suite (Collaborative Computational Project, 1994). The NB1 TCR structure was 
determined by molecular replacement using the Phaser program (Read, 2001) with the 
LC13 TCR as the search model (Protein Data Bank accession number, 1KGC) (Kjer-
Nielsen et al., 2002), and the H-2Db structure was determined by molecular 
replacement using the Phaser program (Read, 2001) with H-2Db as the search model 
(Protein Data Bank accession number, 4L8D) (Valkenburg et al., 2013). Manual model 
building was conducted using Coot software (Emsley and Cowtan, 2004), followed by 
maximum-likelihood refinement with Buster. The NB1 TCR was numbered according to 
the IMGT unique numbering system (Lefranc, 2003). The final models were validated 
using the Protein Data Bank validation web site, and the final refinement statistics are 
summarized in Table S2. All molecular graphics representations were created using 
PyMol (DeLano, 2002). 
 
Surface plasmon resonance 
	 	
Surface plasmon resonance experiments were conducted at 25°C on a BIAcore 3000 
instrument using 10 mM Tris-HCl (pH 8) and 150 mM NaCl supplemented with 1% BSA 
and 0.005% surfactant P20. The TCRs (wt or mutant) were immobilized on research-
grade CM5 chips via standard amine coupling. All experiments were carried out at least 
twice in duplicate as described previously (Gras et al., 2009) across a H-2Db-GAP5040-48 
(wt or mutant) concentration range of 0.78–200 μM. Data were analyzed using 
BIAevaluation version 3.1 with the 1:1 Langmuir binding model. 
 
Quantification and Statistical Analysis 
Statistical differences between two study groups were evaluated using an unpaired, 
two-tailed t test. Statistical differences between more than two study groups were 
evaluated using a one-way ANOVA with Tukey’s multiple comparison post-hoc test. Bar 
graphs display mean ± SD for representative experiments and mean ± SEM for 
combined experiments. Statistical significance was assigned as *p < 0.05, **p < 0.01, 
***p < 0.001 and ****p < 0.0001. Statistical analyses were performed using Prism 7 
software (GraphPad). 
 
Data and Software Availability 
Structural coordinates were submitted to the Protein Data Bank with accession codes 
5WLI for H-2Db-GAP5040-48 and 5WLG for the NB1 TCR in complex with H-2Db-
GAP5040-48. 
	 	
 
REAGENT or 
RESOURCE 
SOURCE IDENTIFIER 
Antibodies 
Anti-mouse CD8α 
(clone 53-6.7) 
BioLegend Cat# 100725 
Anti-mouse CD11a 
(clone M17/4) 
BioLegend Cat# 101107 
Anti-mouse CD90.2 
(clone 30-H12) 
BioLegend Cat# 105306 
Mouse Vβ 
screening Panel 
(Vβ 2, 3, 4, 5.1, 5.2, 
6, 7, 8.1/8.2, 8.3, 9, 
10b, 11, 12, 13, 14 
and 17a) 
BD Pharmingen Cat# 557004 
Anti-mouse IFNγ 
(clone XMG1.2) 
BioLegend Cat# 505809 
Anti-mouse CD5 
(clone 53-7.3) 
BioLegend Cat# 100629 
Anti-mouse CD44 
(clone IM7) 
eBioscience Cat# 11-0441-82 
Anti-mouse CD11b 
(clone M1/70) 
eBioscience Car# 45-0112-82 
Anti-mouse CD11c 
(clone N418) 
eBioscience Cat# 45-0114-82 
Anti-mouse B220 
(clone RA3-6B2) 
eBioscience Cat# 45-0452-82 
Anti-mouse CD3 
(clone 17A2) 
BioLegend Cat# 100309 
Anti-mouse CD4 
(clone RM4-5) 
BD Bioscience Cat# 100536 
Anti-CD16/32 
(clone FCR4G8) 
Thermo Fisher 
Scientific 
Cat# MFCR00 
Tetramers 
H-2Db-TRAP130-138 Prepared In house  NA 
H-2Kb-S20318-326 Prepared In house  NA 
H-2Db-GAP5040-48 Prepared In house  NA 
H-2Kb-OVA257-264 Prepared In house  NA 
H-2Db-GP33-41 Prepared In house  NA 
Other reagents used for flow cytometry 
LIVE/DEAD® 
Fixable Aqua 
Thermo Fisher 
Scientific 
Cat# L34957 
Brilliant Violet 
BV421™ 
Streptavidin 
BioLegend Cat# 405225 
	 	
Chemical and Peptides 
RNAlater® 
Stabilization 
Solution  
Thermo Fisher 
Scientific 
Cat# AM7020 
RNaseOUT™ 
Recombinant 
Ribonuclease 
Inhibitor 
Thermo Fisher 
Scientific 
Cat# 10777019 
10mM dNTP mix Thermo Fisher 
Scientific 
Cat# 18427013 
SYBR® Gold 
Nucleic Acid Gel 
Stain 
Thermo Fisher 
Scientific 
Cat# S-11494 
S.O.C. medium Thermo Fisher 
Scientific 
Cat# 15544034 
SYBR® Safe DNA 
Gel Stain 
Thermo Fisher 
Scientific 
Cat# S33102 
TrackIt™ 
Cyan/Orange 
Loading Buffer 
Thermo Fisher 
Scientific 
Cat# 10482-028 
GeneRuler 1kb 
DNA ladder, ready-
to-use 
Thermo Fisher 
Scientific 
Cat# SM0313 
LPS Sigma Cat# L-8274 
Brefeldin A (1,000x) BioLegend Cat# 420601 
Collagenase Type II Gibco Cat# 17101-015 
DNase Sigma-Aldrich Cat# D4513-1VL 
Percoll GE Healthcare Cat# 17-0891-01 
VitaLyse CMDG Cat# WBL0100 
TRAP130-138 peptide  BioSynthesis Inc Lot# T7825-2 
S20318-326 peptide  BioSynthesis Inc Lot# T7825-3 
GAP5040-48 peptide 
SQLLNAKYL 
BioSynthesis Inc Lot# T7982 
GAP5040-48 peptide 
mutant 
AQLLNAKYL  
BioSynthesis Inc Lot# P1168-1 
GAP5040-48 peptide 
mutant 
SALLNAKYL  
BioSynthesis Inc Lot# P1168-2 
GAP5040-48 peptide 
mutant 
SQALNAKYL  
BioSynthesis Inc Lot# P1168-3 
GAP5040-48 peptide 
mutant 
SQLANAKYL 
BioSynthesis Inc Lot# P1168-4 
	 	
GAP5040-48 peptide 
mutant 
SQLLNAAYL 
BioSynthesis Inc Lot# P1168-5 
GAP5040-48 peptide 
mutant 
SQLLNAKAL 
BioSynthesis Inc Lot# P1168-6 
NB1, KL1 and KL4 
TCR constructs 
DNA from Genscript NA 
H-2Db-GAP5040-48, 
NB1, KL1 and KL4 
TCR proteins 
In house Ref: (Day et al., 2011) 
Commercial Assays 
anti-CD11c 
MicroBeads 
Miltenyi Biotec Cat# 130-108-338 
Anti-PE 
MicroBeads 
Miltenyi Biotec Cat# 130-048-801 
Anti-APC 
MicroBeads 
Miltenyi Biotec Cat# 130-090-855 
μMACS mRNA 
isolation kit 
Milteniyi Biotec Cat# 130-075-201 
SMARTer® RACE 
5’/3’ Kit 
Clontech Cat# 634859 
SuperScript® II 
Reverse 
Transcriptase 
Thermo Fisher 
Scientific 
Cat# 18064014 
TOPO® TA 
Cloning® Kit for 
Sequencing with 
One Shot® MAX 
Efficiency® DH5α-
T1R E. coli 
Thermo Fisher 
Scientific 
Cat# K459540 
Deposited Data 
H-2Db-GAP5040-48 
structure 
PDB web site PDB: 5WLI 
NB1 TCR-H-2Db-
GAP5040-48 
structure 
PDB web site PDB: 5WLG 
Experimental models: Cell lines 
Mouse: primary 
lymphocytes 
This manuscript NA 
Flt-3L tumor cell 
line 
Ref: (Mach et al., 2000) B16-FLT3L (RRID:CVCL_IJ12) 
 
Experimental models: Organisms/Strains 
Mouse: C57BL/6J Harty Laboratory and 
National Cancer 
Institute 
#556 
Deleted: PDB
Deleted: PDB
	 	
Mouse: CB6F1 National Cancer 
Institute 
#566 
Mouse: BALB/c Harty Laboratory and 
National Cancer 
Institute 
#555 
Mouse: BALB.b The Jackson 
Laboratory 
001952 
Mouse: (C57BL/6J  
x C57L) F1 
This manuscript NA 
Mouse: C57L The Jackson 
Laboratory 
000668 
 
Mouse: C57Bl/6 
with GAP5040-48- 
specific TCRb chain 
retrogenic 
This manuscript NA 
Mouse: C57Bl/6 
with TRAP130-138- 
specific TCRb chain 
retrogenic 
This manuscript NA 
P. berghei ANKA 
GFP-parasitized 
Anopheles 
stephensi 
NYU Langone Health 
Insectary Core & 
Parasite Culture 
NA 
Recombinant 
virulent L. 
monocytogenes-
GAP5040-48 
This manuscript NA 
Recombinant actA-
inlB- L. 
monocytogenes-
TRAP130-138 
Ref: (Doll et al., 2016) NA 
Recombinant actA-
inlB-  L. 
monocytogenes-
S20318-326 
Ref: (Doll et al., 2016) NA 
Recombinant actA-
inlB-  L. 
monocytogenes-
GAP5040-48 
Ref: (Doll et al., 2016) NA 
Software and Algorithms 
Diva 8 BD Biosciences http://www.bdbiosciences.com 
Sequencher 5.2.3 Gene Codes 
Corporation 
http://www.genecodes.com/sequencher 
	 	
IMGT IMGT®, the 
international 
ImMunoGeneTics 
information system 
http://www.imgt.org 
XDS (Kabsch, 2010) Available online 
http://xds.mpimf-heidelberg.mpg.de/	
Scala (Evans, 2006) Available online 
http://www.ccp4.ac.uk/html/scala.html	
CCP4 (Collaborative 
Computational Project, 
1994) 
Available online 
http://www.ccp4.ac.uk/ 
 
Phaser (Read, 2001) Available online 
http://www.ccp4.ac.uk/html/phaser.html	
Coot (Emsley and Cowtan, 
2004) 
Available online 
www2.mrc-
lmb.cam.ac.uk/personal/pemsley/coot/	
Pymol (DeLano, W.L., 2002) Available online 
https://pymol.org/view	
BIAevaluation  GE Healthcare Version 3.1 
https://www.biacore.com/lifesciences/			
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SUPPLEMENTAL MATERIAL 
 
 
Figure S1 related to Figure 1: TCR Vβ screening of CD8+ T cell populations 
specific for TRAP130-138, S20318-326 and GAP5040-48 
(A-B) Large CD8+ T cell responses specific for TRAP130-138, S20318-326 and GAP5040-48 
were generated in C57Bl/6 mice using a DC-LM prime-boost strategy. (A) The 
magnitude of each antigen-specific response was assessed at day 45 post-infection in 
the blood of immunized mice using the corresponding MHC I tetramer (representative 
flow cytometry plots – left; cumulative graphs – right). Data represent four independent 
experiments (n = 5 mice/group). Bar graphs depict mean ± SD. Significance was 
assessed using a one-way ANOVA with post-hoc Tukey’s multiple comparison test 
(***p<0.001, ****p<0.0001). (B) Distribution of various Vβ chains within different antigen-
specific TCR repertoires, assessed in the blood of DC-LM-immunized mice and 
expressed as % of total tetramer+ CD8+ T cells. Data represent three independent 
experiments (n = 4–5 mice/group). Bars depict mean ± SD. (C) GAP5040-48-specific 
	   	  
CD8+ T cell responses were generated in CB6F1 and BALB/b mice using a DC-LM 
prime-boost strategy. Representative flow cytometry plots show Vβ8.1/8.2 antibody 
staining of tetramer+ cells in the blood of immunized mice. Data represent two 
independent experiments. 
 
  
	   	  
 
Figure S2 related to Figure 1: Tetramer staining of retrogenic CD8+ T cells 
(A, B) GAP5040-48 and TRAP130-138 TCRβ retrogenic mice were generated as described 
in the Methods. The success of TCR reconstitution was assessed in the blood of 
immunologically intact mice using specific MHC I tetramers (n = 5–6 mice/group). 
Representative flow cytometry plots (A) and cumulative graphs (B) showing tetramer 
staining of selected Vβ+ CD8+ T cells (Vβ8.1 for GAP5040-48, Vβ9 for TRAP130-138). Bars 
depict mean ± SD. Significance was assessed using a non-paired, two-tailed t test 
(****p<0.0001).  
 
 
 
  
	   	  
 
Figure S3 related to Figure 1: Conserved features of the GAP5040-48-specific  
CDR3 β loop 
(A–D) Genetic material used for sequence analysis was derived from viable CD3+ CD4– 
CD8+ GAP5040-48 tetramer+ cells sorted from DC-LM-immunized mice. (A) Length 
distribution of CDR3β sequences expressed as % of total number of molecular Vβ8.1+ 
clones (n = 5 mice). (B, C) Usage of Dβ and Jβ elements in CDR3β sequences 
expressed as % of total number of molecular Vβ8.1+ clones (n = 5 mice).  
 
  
	   	  
 
Figure S4 related to Figure 2: Identification of GAP5040-48 residues critical for TCR 
activation 
Representative flow cytometry plots showing IFNγ staining of GAP5040-48-specific CD8+ 
T cells isolated from DC-LM-immunized mice and subsequently restimulated in vitro 
with wt or mutant GAP5040-48 peptides. 
 
  
	   	  
 
 
	   	  
Figure S5 related to Figure 3: Docking strategy of GAP5040-48-specific TCRs 
(A–I) SPR analysis of GAP5040-48-specific TCRs isolated from the KL1, KL2 and NB1 
CD8+ T cell clones (Supplementary Table 5) to the indicated mutant H-2Db molecules 
presenting the GAP5040-48 peptide. Ala mutations were introduced at selected sites 
based on the crystal structure of the NB1 TCR-H-2Db-GAP5040-48 complex (Gln65, 
Val72, Gln72, Arg79, Lys146, His155 and Glu163). Ala mutation of Gln149 was used as 
a negative control. Ala substitutions were divided into 3 categories as follows: no impact 
(< 3-fold decrease in affinity) on TCR binding (green); moderate impact (3–5-fold 
decrease in affinity) on TCR binding (orange); and critical impact (> 5-fold decrease in 
affinity) on TCR binding (red). SPR results for H-2Db Ala mutants loaded with the wt 
GAP5040-48 peptide are shown for the KL1 TCR (A), the KL4 TCR (B) and the NB1 TCR 
(C). Experiments were conducted in duplicate. Bars depict SD. ΔΔGeq = RT.ln 
(Kdeqmut/Kdeqwt), where mut designates mutant H-2Db. (D–F) The surface of H-2Db is 
shown in white, and the GAP5040-48 peptide is shown in gray. (G–I) Representative SPR 
binding curves for the NB1 TCR with wt H-2Db-GAP5040-48 (G), Q65A H-2Db-GAP5040-48 
(H) and H155A H-2Db- GAP5040-48 (I). The H-2Db-GAP5040-48 complexes were tested 
across a range of concentrations, indicated by the different colors, up to a maximum of 
200 µM). (J–K) Splenocytes isolated from GAP5040-48-immunized mice were stained 
with wt or mutant MHC I tetramers. Representative flow cytometry plots are shown in 
(J), and summary graphs are shown in (K). Data represent two independent 
experiments (n = 3 mice/group). Bars depict mean ± SD. Significance was assessed 
using a one-way ANOVA (****p<0.0001).  
 
  
	   	  
 
Figure S6 related to Figure 3: Interaction of the conserved Y57 and E67 of the Vβ8 
genes with MHC class I and II molecules 
From left to right: NB1 TCR-H-2Db-SQL, 2C TCR-H-2Kb-EQY [PDB code: 2CKB, 
(Garcia et al., 1998)], YAe62 TCR-I-Ab-3K [PDB code: 3C60, (Dai et al., 2008)] and 
YAe62 TCR-H-2Kb-WIY [PDB code: 3RGV, (Yin et al., 2011)] complexes. The Top 
panels represent the footprint of the CDR2β loop for each TCR (orange) on the surface 
of their respective peptide (pink) and MHC (white) surface.  
The middle panels represent a close up view of the interactions between the CDR2β 
loop (orange) and FWβ (blue) with their peptide (pink sitck) and MHC (white cartoon). 
The Tyr57β and the GLu67β are represented in stick, as well as the residues from the 
pMHC that are in contact with them.  
The bottom panels show a representation of the interaction of the Tyr57β (orange 
dashes) and the Glu67β (blue dashes) with the residues from the peptide (pink box) 
and/or the MHC molecules (gray box). 
 
	   	  
 
 
Figure S7 related to Figure 3: Different location of the Tyr57β between Vβ8.2+ 2C 
TCR and the Vβ8.1+ NB1 TCR 
The panels show a close up view of the TCR Tyr57β and Glu67β interaction with the 
pMHC from the (A) 2C TCR-H-2Kb-EQY [PDB code: 2CKB, (Garcia et al., 1998)] 
complex (green), (B) the NB1 TCR-H-2Db-SQL complex (purple), and (C) a 
superimposition of both of them. The C panel shows that the P8-Tyr of the SQL (purple 
stick) would clash with the location of the Tyr57β (green stick) of the 2C TCR. 
  
	   	  
Table S1 related to Figure 1: CDR3β sequences of Vβ8.1+ GAP5040-48-specific 
transcripts 
CDR3β (amino acid) CDR3β (nucleotide)  Counts 
CASSDWGTDAEQF tgtgccagcagtgattgggggacagatgctgagcagttc 93 
CASSDWGVQDTQY tgtgccagcagtgactggggggtccaagacacccagtac 21 
CASSDWGVQDTQY tgtgccagcagtgattggggggtccaagacacccagtac 20 
CASSDWGNQDTQY tgtgccagcagtgattgggggaaccaagacacccagtac 16 
CASSDWGVQDTQY tgtgccagcagtgactggggggtccaagacacccagtac 14 
CASSDWGNYAEQF tgtgccagcagtgactgggggaactatgctgagcagttc 11 
CASSDWGVQDTQY tgtgccagcagtgactggggggtccaagacacccagtac 11 
CASSDWGNQDTQY tgtgccagcagtgactgggggaaccaagacacccagtac 8 
CASSDWGGGQNTLY tgtgccagcagtgactgggggggaggtcaaaacaccttg 8 
CASSDWGNQDTQY tgtgccagcagtgattggggtaaccaagacacccagtac 6 
CASSDWGRDAEQF tgtgccagcagtgactgggggcgagatgctgagcagttc 5 
CASSHWGGDTQYF tgtgccagcagccactggggtggggacacccagtacttt 5 
CASSDWGNTGQLY tgtgccagcagtgactggggaaacaccgggcagctctac 4 
CASSDWGGVEQY tgtgccagcagtgactgggggggcgttgaacagtacagt 4 
CASSDWGASSYEQY tgtgccagcagtgattggggggccagctcctatgaacag 3 
CASSDWGVDAEQF tgtgccagcagtgactggggggtagatgctgagcagttc 3 
CASSDWGNYAEQF tgtgccagcagtgattggggaaactatgctgagcagttc 3 
CASSDWGGGQNTLY tgtgccagcagtgattgggggggcggtcaaaacaccttg  3 
CASSDFGTADTEVF tgtgccagcagtgatttcgggacagcggacacagaagtc  2 
CASSDWGAQDTQY tgtgccagcagtgactggggagcccaagacacccagtac   2 
CASSDWGGAYEQY tgtgccagcagtgactgggggggcgcgtatgaacagtac   2 
CASSDWGSGNTLY tgtgccagcagtgattgggggtctggaaatacgctctat 2 
CASSDWGGQDTQYF tgtgccagcagtgactgggggggacaagacacccagtac 2 
CASSDWGGQNTLY tgtgccagcagtgactgggggggtcaaaacaccttgtac 2 
CASSDWGGYAEQFF tgtgccagcagtgactgggggggctatgctgagcagttc 2 
CASSDWGQDTQY tgtgccagcagtgactgggggcaagacacccagtacttt 2 
CASSDWGTSPLY tgtgccagcagtgactgggggacctctcccttgtacttt 2 
CASSDWGNYAEQF tgtgccagcagtgactgggggaactatgctgagcagttc 2 
CASSDWGGSQNTLY tgtgccagcagtgattggggggggagtcaaaacaccttg 2 
CASSDWGAAGNTLY tgtgccagcagtgattggggggcggctggaaatacgctc 1 
CASSDWGIYAEQFF tgtgccagcagtgattgggggatctatgctgagcagttc 1 
CASSDWGQGSDYT tgtgccagcagtgattggggacagggctccgactacacc 1 
CASSDFQQDTQYF tgtgccagcagtgatttccagcaagacacccagtacttt 1 
CASSDWGGAETLY tgtgccagcagtgactgggggggcgcagaaacgctgtat 1 
CASSDWGDTGQLY tgtgccagcagtgactggggggacaccgggcagctctac 1 
CASSDWGGVEQY tgtgccagcagtgactgggggggcgttgaacagtacagt 1 
CASSDWGGQNTLY tgtgccagcagtgactgggggggacaaaacaccttgtac 1 
CASSDWGNYAEQF tgtgccagcagtgactgggggaactatgctgagcagttc 1 
CASSDWGSAETLY tgtgccagcagtgattgggggagtgcagaaacgctgtat 1 
CASSDWGSQNTLY tgtgccagcagtgattggggtagtcaaaacaccttgtac 1 
CASSDWGVYAEQF tgtgccagcagtgactggggggtctatgctgagcagttc 1 
 
Blue: V gene; red: D gene; black: N insertion; purple, green, gray, orange, pale blue and 
pink: J genes. 
 
	   	  
Table S2 related to Figures 2 and 3: Data collection and refinement statistics 
 
Data collection H-2Db-GAP5040-48 NB1 TCR-H-2Db-GAP5040-48 
Temperature (K) 100 100 
Resolution range (Å) 48.56  - 2.20 (2.27  - 2.20) 
38.82  - 2.1 
(2.175  - 2.1) 
Space group P21 P21 
Unit cell (Å) 
(°) 
53.27, 159.92, 108.46 
β= 92.33 
115.74, 70.21, 116.49 
β= 108.28 
Total reflections 181134 (17680) 206330 (20547) 
Unique reflections 91389 (9050) 103825 (10315) 
Multiplicity 2.0 (2.0) 2.0 (2.0) 
Data Completeness (%) 99.61 (97.23) 100 (100) 
I/σ(I) 16.10 (4.31) 15.61 (2.42) 
Rpima (%) 3.9 (24.0) 3.4 (34.6) 
Refinement statistics   
Rfactorb (%) 19.4 19.3 
Rfreeb (%) 24.1 23.5 
Non-hydrogen atoms   
Protein 12641 12906 
Water 1262 890 
Rms deviation from ideality   
Bonds lengths (Å) 0.01 0.01 
Bonds angles (°) 1.13 1.14 
Ramachandran plot (%)   
Favored 99.3 95.0 
Outliers 0 0.8 
 
a Rpim = Σhkl [1 / (N-1)] ½ Σi| Ihkl,i- < Ihkl > | / Σ< Ihkl> 
b Rfactor = Σhkl | | Fo | - | Fc | | / Σhkl | Fo | for all data except  5% which were used for Rfree 
calculation. Values in parentheses represent the highest resolution-shell. 
 
 
  
	   	  
Table S3 related to Figure 3 and S5: CDR3 sequences of GAP5040-48 specific TCR 
clones 
 
TCR Vα  CDR3α  Vβ  CDR3β  
NB1 18 CATVYAQGLTF 8.1 CASSDWGDTGQLYF 
KL1 17.1 CAMSPQGGSAKLIF 8.1 CASSDWGNQDTQYF 
KL4 18 CATEGNNAGAKLTF 8.1 CASSDWGNQDTQYF 
 
In IMGT nomenclature, Vα17.1 corresponds to TRAV16D/DV11, Vα18 corresponds to 
TRAV8-2, and Vβ8.1 corresponds to TRBV13-3. 
  
	   	  
Table S4 related to Figure 3: Contacts between the NB1 TCR and the H-2Db-
GAP5040-48 complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CDR: complementary-determining regions; HB: hydrogen bonds (cut-off = 3.5 Å),  
VDW: van der Waals (cut-off = 4 Å), SB: salt bridge (cut-off = 5Å).  
  
TCR region TCR residues H-2Db residues Bond type 
CDR1α Thr27-Oγ1 Arg62-NH2 VDW, HB 
CDR1α Tyr28-OH Glu163, Glu166-Oε2, Trp167 VDW, HB 
CDR1α Thr30 Glu163 VDW 
CDR2α Arg57 Ala158 VDW 
CDR2α Ser58-Oγ Ala158-O, Gly162, Glu163-N VDW, HB 
CDR2α Asn59-Nδ2 Ala158, Glu161-Oε1, Gly162 VDW, HB 
CDR3α-J Tyr108-OH Glu58-O, Arg62, Gln65 VDW, HB 
CDR3α-J Ala109 Arg62, Lys66 VDW 
CDR3α-J Gln110-Oε1 Gly69, Gln72-Nε2 VDW, HB 
CDR1β Tyr31-OH Gln72-Nε2 VDW, HB 
CDR2β Tyr57 Gln72, Val76 VDW 
CDR2β Val58 Val76, Arg79 VDW 
CDR3β-D Asp108-Oδ2 Ser150-O VDW, HB 
CDR3β-D Trp109 Ser150, Gly151, His155 VDW 
CDR3β-J Thr112-Oγ1 His155-Nε2 VDW, HB 
TCR region TCR residues GAP5040-48 peptide residues Bond type 
CDR3α-J Ala109 Leu4 VDW 
CDR3α-J Gln110 Leu4 VDW 
CDR1β Asn28-O Lys7-NZ VDW, HB 
CDR1β Asp30-Oδ2 Lys7-NZ, Tyr8 VDW, SB 
CDR1β  Tyr31 Tyr8 VDW 
CDR2β Tyr57-O Tyr8-OH VDW, HB 
CDR3β-D Asp108-Oδ1-O Lys7-NZ VDW, SB 
CDR3β-D Trp109 Ala6 VDW 
	   	  
Table S5 related to Figures 3 and S5: Equilibrium binding affinities of different 
GAP5040-48-specific TCRs and selected H-2Db Ala mutants loaded with wt peptide 
 
 
 
 
 
 
 
 
 
 
 
 
Data represent at least two independent experiments performed in duplicate using 
surface plasmon resonance (mean ± SEM).  
MHCp complex KL1 TCR (Kdeq µM) 
KL4 TCR 
(Kdeq µM) 
NB1 TCR 
(Kdeq µM) 
H-2Db-GAP5040-48 27.8 ± 0.3 7.5 ± 0.2 19.0 ± 0.3 
H-2Db-Q65A-GAP5040-48 23.1 ± 1.0 2.5 ± 0.1 16.3 ± 0.3 
H-2Db-Q72A-GAP5040-48 152.0 ± 4.0 22.4 ± 0.2 80.5 ± 1.3 
H-2Db-V76A-GAP5040-48 > 200 196.0 ± 2.0 > 200 
H-2Db-R79A-GAP5040-48 55.6 ± 1.0 12.0 ± 0.2 50.0 ± 1.4 
H-2Db-K146A-GAP5040-48 > 200 121.5 ± 3.5 > 200 
H-2Db-Q149A-GAP5040-48 29.3 ± 0.7 5.5 ± 0.1 21.8 ± 0.2 
H-2Db-H155A-GAP5040-48 111.0 ± 11.0 77.7 ± 3.6 115.5 ± 11.5 
H-2Db-E163A-GAP5040-48 39.2 ± 2.1 7.4 ± 0.1 27.4 ± 1.0 
	   	  
Table S6A related to Figure 4: Mouse CDR1β sequence alignment  
 
Mouse Vβ CDR1β 
8.1 NNHDY 
10.1 LGHDT 
28.1 MKHDS 
13.1 SGHDT 
9.1 MNHDT 
6.1 FNHDT 
 
CDR1β residues of the Vβ8.1+ NB1 TCR critical for H-2Db-GAP5040-48 recognition are 
depicted in red (Asp30β and Tyr31β). Listed are mouse Vβ gene segments with a 
common Asp30β residue (in bold). Tyr31β is unique to the Vβ8.1 gene. 
 
 
Table S6B related to Figure 4: Mouse CDR2β sequence alignment 
  
 
 
CDR2β residues of the Vβ8.1+ NB1 TCR moderately important for H-2Db-GAP5040-48 
recognition are depicted in blue (Tyr57β and Val58β). Listed are mouse Vβ gene 
segments with a common Val58β residues (in bold). 
 
 
 	  
Mouse Vβ CDR2β 
8.1 SYVADS 
15.1 STVNSAI 
1.1 YSVKQL 
